ASCT remains at the forefront of multiple myeloma therapy

ASCT remains at the forefront of multiple myeloma therapy

VJHemOnc

1 year
50 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Despite recent advances in drug development, autologous stem cell transplant (ASCT) is still, to date, the most effective treatment for multiple myeloma (MM). Speaking from the 1st European Myeloma Network Meeting (EMN) in Turin, Italy, Vittorio Montefusco, MD, of the IRCCS Foundation, National Cancer Institute of Milan, Milan, Italy, explains why this is the case. Dr Montefusco outlines the benefits of using drugs in combination with ASCT, and highlights how the difference in patient fitness between older and younger populations can influence the course of treatment.
Up Next Autoplay